Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291613 · ClinicalTrials.gov registry record · NA
Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management
A NA study, sponsored by Klein Buendel.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03291613 is a NA study that has completed, run by Klein Buendel. The registered enrollment target is 13 participants.
The verdict
NCT03291613, a NA study, has completed, sponsored by Klein Buendel.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet assessments to identify type, intensity, frequency, and phase of pain among SCD adolescents is lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve their self-care. Pinpoint is an interactive gaming tablet app that will be developed with the significant input of clinical experts to assist SCD teens with better identification and self-report of their pain.
Interventions
- OTHER Pinpoint App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-01-15 |
| Est. Completion | 2017-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03291613
The ClinicalTrials.gov registry entry for NCT03291613 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Klein Buendel, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pinpoint App is the first listed.
NCT03291613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03291613 about?
NCT03291613 is a clinical study titled "Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management". Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet assessments to identify type, intensity, frequency, and phase of pain among SCD adolescents is lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especi...
What is the current status of trial NCT03291613?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2017-01-15. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT03291613?
The interventions under investigation include: Pinpoint App (OTHER).
Who is sponsoring clinical trial NCT03291613?
This trial is sponsored by Klein Buendel, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.